Fig. 1From: Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantationOutline of the BEST-Fluids trial. ESKD, end-stage kidney disease; CKD, chronic kidney diseaseBack to article page